Associated Papers
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival.
Dhotare PS et al.
Bmc Cancer, 2025
Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications.
Ji M et al.
Cancers, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Elife, 2025
MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients.
Rivas S et al.
International Journal of Molecular Sciences, 2024
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Biorxiv : the Preprint Server for Biology, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
Marks JA et al.
Lung Cancer (amsterdam, Netherlands), 2024
Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy.
Bumpers QA et al.
Journal of Medicinal Chemistry, 2024
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Garrido J et al.
Bmc Cancer, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.
Estevam GO et al.
Biorxiv : the Preprint Server for Biology, 2024
Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Zhao X et al.
Clinical Chemistry, 2024
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Caswell DR et al.
Nature Genetics, 2024
Network-based prediction approach for cancer-specific driver missense mutations using a graph neural network.
Hatano N et al.
Bmc Bioinformatics, 2023
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G et al.
Cancers, 2023
Overview of Molecular Detection Technologies for MET in Lung Cancer.
Heydt C et al.
Cancers, 2023
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer.
Zhou J et al.
Signal Transduction and Targeted Therapy, 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
An In silico Approach towards Finding the Cancer-Causing Mutations in Human MET Gene.
Laskar FS et al.
International Journal of Genomics, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2022
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
Ma P et al.
Anti-cancer Drugs, 2022
Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
Li S et al.
Anti-cancer Drugs, 2022
MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report.
Choi W et al.
Translational Lung Cancer Research, 2022
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
Sebai M et al.
Human Mutation, 2022
Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease.
Blaquier JB et al.
Drugs in Context, 2022
Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting.
Ai X et al.
Therapeutic Advances in Medical Oncology, 2022
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.
Rosell R et al.
British Journal of Cancer, 2021
First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met.
Majem M et al.
European Journal of Cancer (oxford, England : 1990), 2021